3SBio Inc stock (HK1530013386): recent earnings highlight China biotech growth ambitions

Chinese biopharma group 3SBio Inc has reported its latest annual results and updated investors on its pipeline, offering insights into its role in China’s growing healthcare market and its relevance for global and US-focused biotech investors.

Chinese biopharmaceutical company 3SBio Inc, listed in Hong Kong, has recently updated investors with its latest full-year 2024 results and business outlook, detailing revenue growth in core therapeutics and continued investment in biologics manufacturing and R&D, according to a company announcement released on 03/27/2025 on the Hong Kong Stock Exchange and the group’s investor relations website (3SBio investor relations as of 03/27/2025).

In that update, 3SBio reported higher sales for its key biologic products in nephrology, oncology and dermatology for the year ended 12/31/2024, while also outlining an expanded clinical pipeline in biosimilars and innovative biologics in China, according to the same filing and accompanying presentation materials (HKEX filing as of 03/27/2025).

As of: 05/16/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: 3SBio
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: China
• Core markets: China prescription drug and biologics markets
• Key revenue drivers: Biologic therapies in nephrology, oncology and dermatology; contract manufacturing
• Home exchange/listing venue: Hong Kong Stock Exchange (ticker if verified: 1530.HK)
• Trading currency: Hong Kong dollar (HKD)

3SBio Inc: core business model

3SBio focuses on the research, development, manufacturing and commercialization of biologic and small-molecule drugs, mainly serving the Chinese hospital and specialist clinic market. The company’s portfolio includes therapies in nephrology, oncology, autoimmune diseases and dermatology, where biologics and high-end injectables are increasingly used for chronic disease management, according to its corporate profile and product overview published on 3SBio’s website (3SBio corporate information as of 02/15/2025).

The company operates a vertically integrated model that combines in-house R&D, process development, large-scale biologics manufacturing and commercial distribution. This allows 3SBio to bring proprietary products and licensed-in therapies to market while also acting as a contract development and manufacturing organization (CDMO) for selected partners, according to its annual report for the year ended 12/31/2024, which was made available to investors on 03/27/2025 (3SBio annual report as of 03/27/2025).

Within China’s healthcare system, 3SBio emphasizes hospital-based sales channels, including provincial and national reimbursement lists that can meaningfully influence prescription volumes. The company’s salesforce and distribution partners target specialists in nephrology, oncology and dermatology, where biologic drugs often command higher prices than traditional generics but must compete aggressively within national volume-based procurement schemes, as described in the 2024 results commentary published alongside its earnings update on 03/27/2025 (3SBio results commentary as of 03/27/2025).

3SBio’s business model also involves strategic partnerships and license agreements with international pharmaceutical and biotech firms to co-develop or commercialize products in China. These collaborations typically provide access to late-stage or approved therapies while sharing development costs and regulatory risk, according to the partnership disclosures in its 2024 annual report and associated investor presentation released on 03/27/2025 (HKEX annual filing as of 03/27/2025).

Main revenue and product drivers for 3SBio Inc

3SBio’s revenue base is diversified across several therapeutic franchises, with nephrology treatments historically accounting for a large share of sales. The company markets erythropoietin (EPO) products and related supportive therapies used to treat anemia in patients with chronic kidney disease, which remain significant contributors to operating income, according to the segment breakdown in its results for the year ended 12/31/2024 published on 03/27/2025 (3SBio financial results as of 03/27/2025).

Oncology and supportive care products have become increasingly important, with 3SBio highlighting growth from monoclonal antibodies and targeted therapies used in cancer-related indications. The company’s 2024 earnings materials noted double-digit revenue expansion in selected oncology drugs compared with 2023, alongside continued penetration of newer indications in China, according to its presentation slides released with the 03/27/2025 results announcement (3SBio earnings presentation as of 03/27/2025).

Dermatology and autoimmune offerings, including treatments for psoriasis and other inflammatory skin conditions, form a third pillar of growth. These products tap into rising diagnosis rates and patient awareness in major Chinese cities, while government policies continue to encourage the use of more cost-effective biologics and biosimilars, as described in the company’s 2024 management discussion and analysis section, dated 03/27/2025 (3SBio MD&A as of 03/27/2025).

In addition to proprietary brands, 3SBio generates revenue through its biologics manufacturing and CDMO operations, producing both in-house and partnered products. The company has invested in multiple manufacturing facilities that comply with Chinese and selected international good manufacturing practice standards, with capacity expansions mentioned in its 2024 annual report dated 03/27/2025 (3SBio manufacturing overview as of 03/27/2025).

Looking ahead, management has indicated that pipeline assets, including biosimilars to internationally marketed biologics and novel antibody therapies, are expected to become larger contributors over the medium term. Several candidates were reported to be in Phase 2 or Phase 3 clinical development in China as of the end of 2024, with detailed timelines outlined in the pipeline table included in the 2024 results release on 03/27/2025 (3SBio pipeline disclosure as of 03/27/2025).

Conclusion

3SBio Inc offers investors exposure to China’s expanding biologics and specialty pharmaceuticals market through a portfolio spanning nephrology, oncology and dermatology, supported by in-house R&D and manufacturing capabilities. The company’s latest full-year 2024 results show ongoing revenue growth and continued investment in clinical development and capacity expansion, according to its March 2025 filings. For US-focused investors tracking global biotech trends, 3SBio’s Hong Kong listing and China-centric operations underline both the opportunities in a rapidly growing healthcare system and the region-specific regulatory, pricing and currency risks that can affect performance over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.